Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
MWN-AI** Summary
Therma Bright Inc., a Toronto-based developer of advanced medical devices, announced on October 10, 2025, the appointment of Michael Raimondo to its Board of Directors. With over 30 years of experience in the healthcare sector, Raimondo was previously an advisory board member, indicating a transition to a more integral role within the company.
Recognized for his expertise in sales negotiations, Raimondo has accumulated over $500 million in sales contracts throughout his career. His significant experience includes key leadership positions at Abbott, where he focused on commercial strategy and business development. Currently, he serves as the Commercial Lead for Delphine Diagnostics in New Jersey and is a Managing Partner at The Potentia Group, specializing in consulting and sales leadership in the U.S. healthcare market. Additionally, Raimondo holds a board position at Marketsmith, a prominent independent media and marketing agency in the U.S.
CEO Rob Fia expressed enthusiasm about Raimondo’s strategic involvement in accelerating market penetration and sales growth for Venowave, Therma Bright’s flagship medical device designed to address vascular issues, including deep vein thrombosis. Raimondo noted his commitment to leveraging his commercial experience to build a high-performance sales team and expand the company’s market reach through partnerships with medical device resellers.
The announcement comes alongside the resignation of board member Alex Saringer, with the company thanking him for his service. Therma Bright remains focused on innovative medical solutions, trading on TSXV, OTCQB, and FSE, and continues to address significant healthcare challenges through its proprietary technologies. The company urges caution regarding forward-looking statements, acknowledging inherent risks and uncertainties in achieving projected outcomes.
MWN-AI** Analysis
Therma Bright Inc. (TSXV: THRM) has bolstered its Board of Directors by appointing Michael Raimondo, a seasoned healthcare veteran, which signals a strategic move to enhance its market presence and accelerate the growth of its flagship product, Venowave. With Raimondo's extensive experience in sales and operations within the healthcare sector, including a successful track record at Abbott, investors may see a positive trajectory for Therma Bright.
Raimondo's expertise in market strategy and commercial negotiations—demonstrated through his accomplishment of securing over $500 million in sales contracts—will likely translate into a more robust approach to scaling operations and expanding market reach. His dual role at Delphine Diagnostics and The Potentia Group emphasizes his commitment to driving growth and optimizing commercial strategies. Investors should closely monitor how his contributions could facilitate partnerships with high-value medical device resellers, a significant factor in launching Venowave to the untapped market of individuals afflicted with vascular issues, notably deep vein thrombosis.
In light of this development, potential investors may view Therma Bright as a compelling opportunity to enter a cutting-edge market segment. However, it's crucial to remain aware of the inherent risks outlined in the forward-looking statements. The company's growth projections may be optimistic, but uncertainties exist around the execution of strategies, market reception of Venowave, and competitive pressures within the medical device industry.
As Therma Bright undertakes this transition with Raimondo on board, focusing on the successful implementation of a high-performance sales team will be imperative. Investors should keep an eye on the company's quarterly performance updates following this leadership change to assess how effectively they are capturing market share and driving sales growth. Overall, this appointment appears promising, but prudent investors should maintain a cautious optimism while staying informed of further updates.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board, previously announced on August 13, 2024.
Mr. Raimondo is a distinguished executive and strategist known for his extensive commercial leadership experience in the healthcare and business services sectors across the USA. Mr. Raimondo specializes in sales negotiations, which has successfully led to over $500 million in sales contracts.
He is a retired veteran of the global healthcare industry, having concluded a successful tenure at Abbott, where he held significant senior leadership positions focusing on commercial strategy and business development.
Following his career at Abbott, Mr. Raimondo transitioned into key advisory and executive roles across various organizations. He currently serves as the Commercial Lead for Delphine Diagnostics in New Jersey (NJ), where he drives market strategy and business growth.
Demonstrating his broad expertise, he also serves as a Managing Partner at The Potentia Group, which specializes in negotiations training, sales leadership development and consulting within the U.S. healthcare market. Michael is an active member of the board for Marketsmith one of the largest woman-owned and operated independent media and marketing agencies in the USA. Michael has a BS in physics and minor in mathematics from Kutztown University, and has served on the board of the Make A Wish Foundation for the Ohio-Kentucky-Indiana region.
Rob Fia, CEO, commented, "We are excited to announce that Michael is joining us in a strategic role, transitioning from Advisory Board Member to full Board Member, where we will fully utilize his extensive commercial expertise. Michael's deep industry knowledge will assist Therma Bright to accelerate market penetration and to drive sales growth of Venowave, our flagship medical device."
Michael Raimondo commented: "I am pleased to be joining the Board and contributing to the significant growth potential of the Venowave platform. My primary focus will be on leveraging my commercial experience to rapidly scale the organization-specifically by designing and implementing a high-performance, results-driven internal sales team. Simultaneously, I look forward to enhancing our market reach by expanding our channels through strategic partnerships with high-value medical device resellers, ensuring Venowave reaches patients suffering from vascular issues, such as the 900,000 citizens who suffer from deep vein thrombosis each year per the US CDC."
Therma Bright announces the resignation of Board member Alex Saringer. The Company would like to thank Alex for his service.
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269945
FAQ**
How does the appointment of Michael Raimondo to the Board of Directors of Therma Bright Inc. (THRM:CC) influence the company’s strategic direction in the competitive healthcare market?
Given Michael Raimondo's experience, what specific strategies can we expect Therma Bright Inc. (THRM:CC) to implement in order to enhance the sales growth of the Venowave platform?
With approximately 900,000 citizens in the U.S. suffering from deep vein thrombosis, how does Therma Bright Inc. (THRM:CC) plan to increase market penetration for Venowave in this segment?
What were the main contributions of the departing board member Alex Saringer to Therma Bright Inc. (THRM:CC), and how might his resignation impact the company’s future initiatives?
**MWN-AI FAQ is based on asking OpenAI questions about Therma Bright Inc (OTC: TBRIF).
NASDAQ: TBRIF
TBRIF Trading
0.0% G/L:
$0.0444 Last:
1,100 Volume:
$0.0444 Open:
